Oisin Biotechnologies
Oisín Biotechnologies is focused on developing genetic medicines for health and longevity. They have a robust pipeline targeting multiple drivers of age-related conditions, including programs that stimulate muscle growth, selectively kill fat cells, and remove senescent cells. Their therapies leverage a new, non-viral delivery technology called Fusogenix™ Proteo-Lipid Vehicle (PLV), which enables extensive biodistribution for DNA and RNA payloads and permits safe repeated dosing.
Industries
Nr. of Employees
small (1-50)
Oisin Biotechnologies
Products
Therapeutic program for stimulating muscle growth
A preclinical genetic medicine program aimed at stimulating muscle growth to address frailty.
Adipocyte-targeted ablation program
A preclinical genetic medicine program focused on selective killing of fat cells.
Senescent-cell removal program
A preclinical genetic medicine program designed to remove senescent cells as a driver of age-related dysfunction.
Therapeutic program for stimulating muscle growth
A preclinical genetic medicine program aimed at stimulating muscle growth to address frailty.
Adipocyte-targeted ablation program
A preclinical genetic medicine program focused on selective killing of fat cells.
Senescent-cell removal program
A preclinical genetic medicine program designed to remove senescent cells as a driver of age-related dysfunction.
Services
Preclinical manufacturing services
Process development and in-house manufacturing support for preclinical genetic medicine programs.
Preclinical manufacturing services
Process development and in-house manufacturing support for preclinical genetic medicine programs.
Expertise Areas
- Genetic medicine development
- Aging and geroscience research
- Non-viral delivery systems for nucleic acids
- Preclinical manufacturing and process development
Key Technologies
- Non-viral proteo-lipid delivery
- DNA payload delivery
- RNA payload delivery
- Extrahepatic biodistribution